Fuglum E, Schillinger A, Andersen J B, Belstad B E, Jensen D, Müller F, Müller K J, Schulstad B, Elgen K
Moss Sykehjem, Norway.
Pharmatherapeutica. 1989;5(5):285-91.
A double-blind study was carried out in 48 hospitalized, elderly demented patients with key symptoms of aggressiveness and agitation to evaluate the efficacy and tolerability of zuclopenthixol compared with that of haloperidol/levomepromazine. Patients were allocated at random to receive initial doses of either 4 mg zuclopenthixol daily or 1 mg haloperidol in the morning and 5 mg levomepromazine in the evening over a period of 4 weeks. In Week 4, the mean daily dose was 4.8 mg zuclopenthixol and 1.6/7.6 mg haloperidol/levomepromazine, respectively. After 1 week, the severity of illness was already significantly reduced, and was further reduced after 2 and 4 weeks of treatment in both groups: the reduction, however, was most pronounced in the zuclopenthixol group and after 2 weeks this difference was significant. Side-effects were few. The results of the study indicate that, whilst both zuclopenthixol and haloperidol/levomepromazine were effective and well tolerated in these elderly patients with aggressiveness and agitation, onset of therapeutic effect appeared more rapidly with zuclopenthixol, which furthermore provides the practical advantage that it may be administered once a day.
对48名住院的、患有攻击性和激越等关键症状的老年痴呆患者进行了一项双盲研究，以评估氯哌噻吨与氟哌啶醇/左美丙嗪相比的疗效和耐受性。患者被随机分配，在4周的时间里，每天初始剂量接受4毫克氯哌噻吨，或早上接受1毫克氟哌啶醇，晚上接受5毫克左美丙嗪。在第4周时，氯哌噻吨的平均日剂量为4.8毫克，氟哌啶醇/左美丙嗪的平均日剂量分别为1.6/7.6毫克。1周后，病情严重程度已显著降低，两组在治疗2周和4周后病情进一步减轻：然而，氯哌噻吨组的减轻最为明显，2周后这种差异具有显著性。副作用很少。研究结果表明，虽然氯哌噻吨和氟哌啶醇/左美丙嗪在这些患有攻击性和激越症状的老年患者中均有效且耐受性良好，但氯哌噻吨的治疗效果起效更快，而且它还有每天只需给药一次的实际优势。
